Monitored campaign email
Use this route for campaign scrutiny, source questions, policy engagement, media enquiries, accessibility feedback, or privacy questions. Contact: [email protected]. It is not a clinical advice route.
Email the campaignContact
Contact the campaign
This campaign welcomes serious engagement from MPs, NHS and prescribing stakeholders, charities, clinicians, researchers, advocates, and journalists. It cannot provide medical advice or respond to urgent clinical concerns.
Monitored email
Email the campaign at [email protected] for policy, evidence, media, or accessibility enquiries.
Do not send urgent medical information, detailed medical histories, clinical photos, or identifiable information about another person. A consent-led patient evidence route is being prepared, but it is not live.
Who should contact
Route the enquiry by role.
The campaign cannot provide medical advice or urgent clinical support.
MPs and parliamentary offices
Use the campaign to ask how documented first-line emollient failure is handled and how total eczema care cost is assessed.
NHS, NICE, ICB and prescribing stakeholders
Scrutinise the source trail, challenge weak claims, and review whether current pathways are flexible enough after documented failure.
Charities, clinicians, researchers and advocates
Help identify missing citations, evidence gaps, and careful public wording that does not become product promotion.
Journalists
Use the evidence labels and source trail when covering the campaign. Please keep patient testimony separate from clinical proof.
Patients and carers
A consent-led patient evidence route is being prepared, but it is not live. Please do not send detailed health information, medical histories, photos, urgent clinical information, or identifiable third-party information by email or through this website.
Safety note
For personal clinical concerns, speak to a GP, pharmacist, nurse, dermatologist, NHS 111, or another qualified NHS service. Call 999 or emergency services for serious or life-threatening symptoms, severe allergic reaction, breathing difficulty, or immediate danger.
FOI and evidence gathering
Formal evidence-gathering is underway. FOI requests are submitted and responses are pending, so they should not be cited as findings yet.
View FOI requestsWhat we need next
The campaign is looking for scrutiny, evidence review, and public-interest engagement.
These are launch-safe ways to help the campaign improve without collecting patient health data through the website.
Evidence review
Help test whether current wording is supported by reliable sources and where claims should remain bounded.
Policy scrutiny
Review the campaign asks against NHS, NICE, ICB, formulary, and primary-care prescribing routes.
FOI response analysis
Help interpret responses when they arrive, including refusals, limitations, missing data, and what can safely be concluded.
Public route examples
Identify public formulary, access, exception-route, or review examples that can be cited without collecting patient histories.
Media and charity engagement
Help present the policy question clearly while keeping evidence boundaries visible and avoiding product or treatment claims.
NHS stakeholder engagement
Challenge the source trail, identify stronger evidence, and scrutinise whether the pathway works after documented first-line failure.
Next step
Use the contact route for campaign scrutiny, not clinical care.
The campaign is seeking evidence review, policy engagement, and careful source work. Patients should not send detailed medical histories or urgent clinical information through this static site.